Xencor (XNCR) Projected to Post Earnings on Wednesday

Xencor (NASDAQ:XNCR) is projected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.3341) per share and revenue of $63.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) EPS. On average, analysts expect Xencor to post ($3.05) EPS for the current fiscal year and ($3.31) EPS for the next fiscal year.

Xencor Stock Performance

Shares of NASDAQ:XNCR opened at $29.99 on Wednesday. Xencor has a 52-week low of $10.38 and a 52-week high of $33.60. The business has a fifty day moving average of $25.56 and a two-hundred day moving average of $16.73.

Key Xencor News

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Updated Phase 1 data for XmAb819 showed a reported 45.5% response rate in heavily pretreated ccRCC patients, with coverage describing the antitumor activity as “impressive,” “unprecedented” and “profound.” Xencor plans to advance the program toward a late-stage trial. Xencor Reveals Updated Phase 1 XmAb819 Data and Projects Cash Runway Through 2029
• Positive Sentiment: The company said its cash resources are expected to fund operations through 2029, reducing near-term financing concerns as it develops XmAb819 and other pipeline programs. Cash Runway and Updated Data
• Positive Sentiment: Analyst sentiment strengthened following the data. Wedbush raised its price target from $30 to $45 and maintained an Outperform rating, while RBC increased its target from $20 to $43 and retained Outperform, though it continues to flag speculative risk. Wedbush Analyst Recommendation RBC Raises Price Target
• Neutral Sentiment: The response data are from a Phase 1 study, so durability, safety, comparative efficacy and confirmation in larger controlled trials remain important uncertainties. The stock is now near its 12-month high after a sharp rally, increasing sensitivity to follow-up data and profit-taking.
• Negative Sentiment: Xencor remains unprofitable, and analysts expect a loss for the full year. XmAb819’s potential FDA accelerated-approval pathway is not guaranteed; disappointing safety or efficacy results could weigh heavily on the shares.

Analyst Ratings Changes

A number of analysts have recently issued reports on XNCR shares. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial upped their price target on Xencor from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Barclays set a $45.00 price target on Xencor and gave the stock an “overweight” rating in a report on Monday. Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald boosted their price objective on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.33.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.

Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.